Cardiac arrest & resuscitation

Impact of the Life-Sustaining Treatment Decision Act on the Incidence and Outcomes of In-Hospital Cardiopulmonary Resuscitation

Crit Care MedPublished Retrospective population-based cohort study

Main finding · In-hospital mortality; annual ASIR of IHCAResult — go to the resultAdjusted odds ratio 0.90 95% CI 0.88–0.92

Authors' conclusion

The enactment of the LSTDA was associated with a significant improvement in survival outcomes and a deceleration in the rising incidence of IHCA.

Study context

Population
Adults (≥ 18 yr) undergoing in-hospital CPR, South Korea, 2013–2023 (implementation year 2018 excluded)
Participants
380,488 adults
Exposure
Post-LSTDA vs pre-LSTDA period
  • post-LSTDAn = 233,103
  • pre-LSTDAn = 147,385reference
Outcome
Annual age-standardized incidence rate (ASIR) of IHCA and in-hospital mortality
Methodological detailsnationwide administrative database, pre-post comparison, segmented linear regression
  • Nationwide administrative database
  • Pre-post comparison
  • Segmented linear regression

Main finding

In-hospital mortality; annual ASIR of IHCA

Adjusted odds ratio

0.90

95% CI 0.88–0.92

P < 0.001

Post-LSTDA vs Pre-LSTDA
aOR 0.90 (95% CI 0.88–0.92); P < 0.001

As reported in the abstract

Age-standardized incidence rate (ASIR) of in-hospital cardiac arrest (IHCA) before the Life-Sustaining Treatment Decision Act (LSTDA): significant increase, cases per 100,000 population per year
6.5 (95% CI, 1.6-11.4; p < 0.001; segmented linear regression)
ASIR of IHCA after implementation: upward trend decelerated, slope change
−5.4 (95% CI, −12.8 to 1.5; p = 0.177)

Observational data: associations, not effects.

Original publication

Impact of the Life-Sustaining Treatment Decision Act on the Incidence and Outcomes of In-Hospital Cardiopulmonary Resuscitation. Crit Care Med. Published 31 March 2026. doi:10.1097/ccm.0000000000007136

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.